CONTACT US: Contact info
|
Citation |
Muanda FT, Blake PG, Weir MA, Bathini L, Chauvin K, Dixon SN, McArthur E, Sontrop JM, Moist L, Kim RB, Garg AX. Am. J. Kidney Dis. 2021; ePub(ePub): ePub. |
|
Copyright |
(Copyright © 2021, National Kidney Foundation, Publisher Elsevier Publishing) |
|
DOI |
|
PMID |
unavailable |
|
Abstract |
Baclofen is a popular muscle relaxant that is eliminated primarily unchanged in the urine. We recently reported a higher risk of encephalopathy in a cohort of 15,942 older adults with chronic kidney disease (CKD) who started baclofen at ≥20 mg/day vs. <20 mg/day; a higher risk was also observed in all baclofen users vs. non-users. In another study of patients receiving dialysis, 1 in 14 were hospitalized with encephalopathy within 3 days of starting baclofen... Language: en |